Moreover, HER2 V777L-mutated breast cancer cell lines showed sensitivity to TKIs: lapatinib and neratinib, thus suggesting a possible role of HER2 targeting also in particular cases of HER2 “ultra-low” breast cancer (Bose et al., 2013). This evidence concerns the gene ERBB2 and breast carcinoma.